Syrian Teen Arrested in Germany for Brutal Murder of Young German Beaten to Death As He Walked Home From Sister’s Graduation
The main suspect in the murder of a young German beaten to death as he walked home from his sister’s graduation on Sunday is an 18-year-old Syrian national already known to the authorities.
Twenty-year-old Philippos T. and his 18-year-old friend were attacked in the early hours of Sunday as they walked home through the German town of Bad Oeynhausen in the state of North Rhine-Westphalia.
Witnesses reported a gang of around 10 “Southern-looking” men confronting the pair before beating them to the ground and kicking them as they lay defenseless. “Southern” is often a description used in Germany for men of Maghreb or Arab origin.
BREAKING: ?? 20-year-old Philippos was beaten to death by approximately 10 “southern” males in the German city of Bad Oeynhausen. “Southern” is usually “code” for Middle Easterners.
— Remix News & Views (@RMXnews) June 25, 2024
The German youth had just come from his sister’s graduation party when he was attacked by the… pic.twitter.com/LvuWgDlNAW
Both victims were beaten so badly that they were hospitalized, and Philippos T. was induced into a coma, one he sadly never woke up from.
On Thursday, German media outlets reported that the main suspect in the case is an 18-year-old Syrian migrant who arrived in Germany back in 2018. He already has a considerable rap sheet, having previously been charged with property and drug offenses.
20-year-old Philippos was induced into a coma after the devastating attack, but he has since died from his injuries. https://t.co/N8b4Y3Lcev
— Remix News & Views (@RMXnews) June 25, 2024
The Bielefeld police announced the suspect had been arrested at an asylum center in the town on Wednesday and is expected to be brought before a judge on Thursday.
The arrest was made following “numerous tips from witnesses and intensive investigative work,” the authorities added.
Democrat Insiders Admit ‘Dementia Ridden’ Biden Will Be Replaced Before November
Democrats are planning to replace Joe Biden with another candidate following Thursday night’s disastrous debate against Donald Trump. According to insiders within the Democratic Party, Biden is suffering from severe dementia and is no longer […]
The post Democrat Insiders Admit ‘Dementia Ridden’ Biden Will Be Replaced Before November appeared first on The People’s Voice.
Macon Warns of ‘Bloodbath’ on the Streets of France if Marine Le Pen Wins
French President Emmanuel Macron has warned of a “civil war” and blood on the streets of France if his rival Marine Le Pen wins the upcoming election. Following Macron’s humiliating defeat to Le Pen earlier […]
The post Macon Warns of ‘Bloodbath’ on the Streets of France if Marine Le Pen Wins appeared first on The People’s Voice.
Scientists Say Liberal Women Are the Most Mentally Unwell Demographic in the World
It’s official – liberal women are the most mentally ill and emotionally unstable demographic in the world, according to a new study. According to new data released by a Pew American Trends Panel study, women […]
The post Scientists Say Liberal Women Are the Most Mentally Unwell Demographic in the World appeared first on The People’s Voice.
LAPD Bombshell: ‘Matthew Perry Was Murdered’
LAPD investigators say they believe Matthew Perry was murdered following revelations that the Friends star was about to name and shame elite pedophiles in Hollywood. According to police insiders, Perry was intentionally given an overdose […]
The post LAPD Bombshell: ‘Matthew Perry Was Murdered’ appeared first on The People’s Voice.
CDC Walks Back Recommendations for RSV Vaccines
U.S. health officials on Wednesday changed their recommendations for respiratory syncytial virus (RSV) vaccines in older adults, narrowing the recommended age group for the shots to adults 75 and older.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) also recommended that among people ages 60 to 74, only those who have an increased risk of severe RSV due to medical conditions should get the shot.
The recommendations replace the previous recommendation that all adults 60 and older may take the shot after consulting with their provider.
The committee also recommended that adults who already received an RSV shot should not receive any type of booster, based on data showing an additional shot did not improve RSV-related outcomes.
ACIP members declined to recommend GSK’s Arexvy RSV vaccine for people ages 50 to 59 at risk for severe RSV, even though the U.S. Food and Drug Administration in June expanded Arexvy’s approval to include that group.
“You shouldn’t vaccinate people who really don’t need the vaccine,” committee member Dr. Oliver Brooks told the group.
The new recommendations may cut the possible U.S. market for RSV shots in 2024-25 from $93 million to about $55 million, Reuters reported.
CDC Director Mandy Cohen accepted the committee’s recommendations, making it the government’s updated guidance for doctors.
Growing evidence of RSV vaccine injuries
Before voting on the changes, the committee discussed the growing evidence of adverse events associated with the RSV vaccine, including the documented risk of Guillain-Barré syndrome (GBS).
GBS is a rare disorder in which the body’s immune system attacks its own nerves. Symptoms can range from brief weakness to paralysis.
ACIP’s Dr. Matthew Daley assured other committee members that GBS is rare.
However, Children Health Defense research scientist Karl Jablonowski, Ph.D., who provided ongoing commentary on the meeting on CHD.TV’s live blog, noted that the presenter was “dancing around the fact that incidence of GBS for RSV is 1 one 47,500, [in data presented] where even for the COVID-19vaccines it was 1 in 700,000.”
Dr. Michael Melgar, co-lead of the Adult RSV Work Group, said the benefits of the shots still outweigh the risks.
There are currently three FDA-approved RSV vaccines on the market. Last year GSK’s (Arexvy) and Pfizer’s (Abrysvo) RSV prefusion F protein-based vaccines were approved by the FDA for adults ages 60 and up, and the two companies have been competing for market share.
The FDA approved Moderna’s mRNA RSV vaccine (mRESVIA) earlier this month for the same age group, with no input from its advisory committee.
James Donahue, DVM, Ph.D., MPH, of the Marshfield Clinic Research Institute in Wisconsin also presented recent surveillance data from the CDC’s Vaccine Safety Datalink analysis revealing a safety signal for immune thrombocytopenic purpura — an illness that can lead to bleeding and bruising — with the GSK RSV vaccine.
Eliminating the shared clinical decision-making model
The new recommendations eliminate the “shared clinical decision-making” model, where a provider and patient work together to determine what healthcare decision is best for the patient based on a person’s individualized risk factors, values and preferences.
The model, a key element for the practice of personalized medicine, is in place for four other adult vaccines.
The committee said the model was difficult and confusing to implement and a universal recommendation is simpler.
Dr. Camille Kotton, chair of the Adult RSV Work Group, said, “We have learned from feedback from healthcare providers that having shared decision-making conversations is not simple,” she said. “Unlike a universal recommendation where there’s a clear call to vaccinate, with shared clinical decision-making the call to action is to discuss with a healthcare provider — a less clear message.”
NBC News said the shared decision-making model is “a likely reason that fewer than 25% of older Americans have gotten a shot.”
Jablonowski told The Defender that in its original recommendation, the committee used shared decision-making as “an escape.” Because there weren’t enough data to support a recommendation for universal vaccination, the committee put the responsibility on the physicians, he said.
Now that they have more data, they are taking the decision out of the hands of the patient and provider, he said.
“The presenter summarized shared clinical decision-making as inconvenient and less clear than a standing recommendation,” Jablonowski blogged. Shared clinical decision-making “is a cornerstone of personalized medicine. US taxpayers have spent billions, probably hundreds of billions of dollars on personalized medicine research. She is really arguing that personalized medicine does not apply to vaccinations.”
In Thursday’s meeting, the CDC’s Lakshmi Panagiotakopoulos, M.D., MPH, also criticized the model while discussing the COVID-19 vaccines. “Shared clinical decision-making would create barriers to vaccination, may not effectively target those higher at risk, and would likely increase inequities in vaccine access,” she said.
Committee member Denise Jamieson, M.D., MPH, also expressed her concern that not enough providers would recommend optional vaccines strongly unless there were universal recommendations.